BioAtla Board Member's $1.2M Stock Award Signals Confidence in Biotech Firm

Rhea-AI Filing Summary

BioAtla Director Sylvia McBrinn received a grant of 23,500 restricted stock units (RSUs) on June 18, 2025. Following this transaction, McBrinn's total direct beneficial ownership increased to 59,125 shares of common stock.

Key details of the RSU grant:

• The RSUs were granted at $0 exercise price
• Vesting occurs 100% on the earlier of June 18, 2026, or the next annual stockholder meeting
• Vesting is contingent on continued service through the vesting date

This Form 4 filing indicates standard equity-based compensation for a board member, which aligns the director's interests with shareholders. The transaction was executed pursuant to the company's director compensation program and represents a significant addition to McBrinn's equity stake in BioAtla.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MCBRINN SYLVIA

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	23,500	$0.00	--

Holdings After Transaction: Common Stock — 59,125 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCBRINN SYLVIA

(Last) (First) (Middle)

C/O BIOATLA, INC. 11085 TORREYANA ROAD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioAtla, Inc. [ BCAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		A		23,500(1)	A	$0	59,125	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date.

	/s/ Christian Vasquez, as Attorney-in-Fact for Sylvia McBrinn	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of BCAB stock did Sylvia McBrinn receive on June 18, 2025?

According to the Form 4 filing, Sylvia McBrinn received 23,500 shares of BCAB common stock in the form of restricted stock units (RSUs) on June 18, 2025.

What is the vesting schedule for BCAB Director Sylvia McBrinn's RSU grant?

The RSUs will vest 100% of the total shares (23,500) on the earlier of: (i) June 18, 2026, or (ii) the next BioAtla annual meeting of stockholders, subject to McBrinn's continued service through the vesting date.

How many BCAB shares does Sylvia McBrinn own after the June 18, 2025 transaction?

Following the reported RSU grant transaction, Sylvia McBrinn beneficially owns 59,125 shares of BCAB common stock directly (indicated by 'D' in the ownership form column).

What was the purchase price of BCAB RSUs granted to Sylvia McBrinn?

The RSUs were granted to Sylvia McBrinn at a price of $0, as shown in the 'Price' column of Table I in the Form 4 filing.

What position does Sylvia McBrinn hold at BCAB?

According to the Form 4 filing, Sylvia McBrinn serves as a Director of BioAtla, Inc. (BCAB), as indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.